A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
Latest Information Update: 30 May 2025
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms BIMES
Most Recent Events
- 01 May 2025 Primary endpoint has not been met. (To evaluate the efficacy of the treatment), according to results published in the Lung Cancer.
- 01 May 2025 Results assessing the efficacy (progression-free survival [PFS]) of bintrafusp alfa in patients with pleural mesothelioma (PM) who had progressed to platinum-based chemotherapy and had not previously received immunotherapy, published in the Lung Cancer.
- 19 Sep 2024 Status changed from recruiting to completed.